The goal of cancer immunotherapy is to enable a patient's immune system to specifically recognize and destroy tumor cells.1 MPDL3280A, an engineered anti-PDL1 antibody, is an investigational cancer immunotherapy designed to target PD-L1 expressed on tumor cells and tumor-infiltrating immune cells.2,3
MPDL3280A is specifically engineered to work in concert with the inherent antitumor mechanisms within the body's immune system.
Please note: this video contains sound so please adjust volume
MPDL3280A: designed to harness the body's own immune system to fight tumor cells
Binding of PD-L1 to its receptors PD-1 and B7.1 on the surface of T cells results in deactivation of the T cells.1
This deactivation occurs when T cells bind to both tumor cells and tumor-infiltrating immune cells, such as T regulatory cells and macrophages.1
MPDL3280A is designed to prevent PD-L1 from binding to PD-1 and B7.1. This blockade of PD-L1 may enable the activation of T cells, restoring their ability to detect and attack tumor cells.2,3
This may further stimulate the immune response by recruiting more T cells to attack the tumor, thus empowering the body's own immune system to fight multiple types of cancer.3
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10. PMID: 23890059
Powderly J, Koeppen H, Hodi FS, et al. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. Presented at: American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2013; Chicago, IL. Study 3001.